Comparison of small molecules and oligonucleotides that target a toxic, non-coding RNA
- 1 June 2016
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (11) , 2605-2609
Abstract
No abstract availableKeywords
Funding Information
- Muscular Dystrophy Association (254929)
This publication has 23 references indexed in Scilit:
- RNA Structures as Mediators of Neurological Diseases and as Drug TargetsNeuron, 2015
- Targeting nuclear RNA for in vivo correction of myotonic dystrophyNature, 2012
- RNA therapeutics: beyond RNA interference and antisense oligonucleotidesNature Reviews Drug Discovery, 2012
- RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic PlatformAnnual Review of Pharmacology and Toxicology, 2010
- Causes and consequences of microRNA dysregulation in cancerNature Reviews Genetics, 2009
- Reversal of RNA Dominance by Displacement of Protein Sequestered on Triplet Repeat RNAScience, 2009
- MicroRNAs in diseases and drug responseCurrent Opinion in Pharmacology, 2008
- Targeting RNA with Small MoleculesChemical Reviews, 2008
- Myotonic dystrophy: RNA-mediated muscle diseaseCurrent Opinion in Neurology, 2007
- Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family memberCell, 1992